Daratumumab

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`DRUG-DARATUMUMAB`
Type	Drug
Aliases	DarzalexDarzalex Faspro (SC)Даратумумаб
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-MM`
Sources	`SRC-NCCN-MM-2025`

Drug Facts

Class	monoclonal_antibody — anti-CD38 IgG1κ (fully human)
Mechanism	Binds CD38, which is highly expressed on plasma cells. Induces myeloma cell death through complement-dependent cytotoxicity (CDC), antibody- dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), apoptosis, and immunomodulation via depletion of CD38+ regulatory T-cells.
Typical dosing	IV: 16 mg/kg weekly cycles 1-2, every 2 weeks cycles 3-6, then every 4 weeks. SC (Faspro): 1800 mg with hyaluronidase, same schedule — preferred where available due to shorter administration time and fewer infusion reactions.
Ukraine registered	True
NSZU reimbursed	True
Ukraine last verified	2026-04-27

Notes

Reimbursement under НСЗУ in Ukraine is currently NOT in place — this is a meaningful access constraint. Patients selected for D-VRd in 1L need documented funding pathway (clinical trial, charitable scheme, or out-of-pocket). HBV screening (HBsAg + anti-HBc) mandatory before first dose; entecavir prophylaxis if HBsAg+ or anti-HBc+. Type and screen for red-cell antibodies BEFORE first dose to avoid daratumumab interference with crossmatching.

Used By

Contraindications

CI-HBV-NO-PROPHYLAXIS - CI-HBV-NO-PROPHYLAXIS

Regimens

REG-D-RD-MAIA - Daratumumab + Lenalidomide + Dexamethasone (D-Rd, MAIA — MM 1L transplant-ineligible)
REG-DARA-LEN-MAINTENANCE - Daratumumab + Lenalidomide maintenance post-ASCT (PERSEUS schedule)
REG-DARA-VRD - Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (D-VRd), 4-6 induction cycles
REG-DKD - Daratumumab + Carfilzomib + Dexamethasone (DKd / D-Kd / Isa-Kd analog), 28-day cycles